Pulmonary Embolism in Vaccine-Induced Thrombotic Thrombocytopaenia: Under-Reported?
Open Access
- 19 October 2021
- journal article
- research article
- Published by European Medical Group in EMJ Respiratory
- p. 79-85
Abstract
Vaccination is currently the most powerful tool for controlling the COVID-19 pandemic.1 In large randomised controlled trials, the approved vaccines have shown good efficacy and safety.2 However, there is increasing concern about the safety of the adenovirus-based COVID-19 vaccines of AstraZeneca (ChAdOx1 nCoV-19) and Janssen (Ad26.COV2.S).Keywords
This publication has 19 references indexed in Scilit:
- Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopeniaDiagnostic and Interventional Imaging, 2021
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021JAMA, 2021
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic ThrombocytopeniaNew England Journal of Medicine, 2021
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationNew England Journal of Medicine, 2021
- Evaluation of laboratory assays for anti‐platelet factor 4 antibodies after ChAdOx1 nCOV‐19 vaccinationJournal of Thrombosis and Haemostasis, 2021
- Thrombosis and Coagulopathy in COVID-19Current Problems in Cardiology, 2021
- Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccineAmerican Journal of Hematology, 2021
- Ebola vaccine trials: progress in vaccine safety and immunogenicityExpert Review of Vaccines, 2019
- Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2017
- The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and AdolescentsPediatrics, 2012